---
title: "China’s Hengrui Pharma Is Hit by Third Delay in US Approval for Liver Cancer Drug"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292323780.md"
description: "China's Hengrui Pharma announced a third delay in US FDA approval for its liver cancer drug, Camrelizumab combined with Rivoceranib. The delay stems from required improvements at the American partner Elevar Therapeutics' manufacturing site following an April inspection. The FDA feedback did not question the drug's safety or efficacy. This follows previous delays in May 2024 and March 2025 due to similar manufacturing issues. Hengrui shares rose slightly in Shanghai and Hong Kong."
datetime: "2026-07-10T12:53:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292323780.md)
  - [en](https://longbridge.com/en/news/292323780.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292323780.md)
generator: "portal-rs"
---

# China’s Hengrui Pharma Is Hit by Third Delay in US Approval for Liver Cancer Drug

(Yicai) July 10 -- China’s Hengrui Pharmaceuticals has announced a third delay in US approval for its liver cancer therapy, due to the need for improvements at its American partner’s drug production site.

The plant was inspected by the US Food and Drug Administration in April, and improvement measures are being taken based on the regulator’s feedback, the Jiangsu province-based company said today. It had passed a European Union inspection last year.

Hengrui Pharma partnered with Elevar Therapeutics to launch a PD-1 drug therapy for liver cancer. The therapy combines Hengrui Pharma’s PD-1 inhibitor Camrelizumab‌ and Rivoceranib from Elevar Therapeutics.

Clinical research results from Hengrui Pharma showed that the median overall survival rate of the treatment group using the PD-1 combined therapy reached 23.8 months. The therapy received market approval from China’s National Medical Products Administration in January 2023.

The company clarified that the FDA’s feedback did not involve any issues regarding the clinical research data, safety, or efficacy of the drug. Hengrui Pharma will communicate closely with the FDA and its US partner to clarify future plans, it said.

The FDA’s previous delays to approving the drug -- first in May 2024 and then in March 2025 -- also related to manufacturing issues.

Shares of Hengrui Pharma \[SHA: 600276\] closed 0.3 percent higher at CNY55.75 (USD8.22) each in Shanghai today, while its Hong Kong-listed stock \[HKG: 1276\] climbed 1.3 percent to finish at HKD59.25 (USD7.56).

Editor: Tom Litting

### Related Stocks

- [01276.HK](https://longbridge.com/en/quote/01276.HK.md)
- [600276.CN](https://longbridge.com/en/quote/600276.CN.md)

## Related News & Research

- [HENGRUI PHARMA  1H26 Net Profit Rises 0.3% YoY to RMB4.465 Billion; Shares Now Down Over 7%](https://longbridge.com/en/news/296422700.md)
- [Hengrui Pharma Advances 2026 Employee Stock Ownership Plan Using Existing A Shares](https://longbridge.com/en/news/296370263.md)
- [Hengrui Pharma launches RMB 1 billion-RMB 2 billion A-share buyback, caps price at RMB 81.78](https://longbridge.com/en/news/296368941.md)
- [2 GLP-1 Stocks That Could Double Your Money by 2031](https://longbridge.com/en/news/296030914.md)
- [Abbisko Wins China IND Nod for Pan-KRAS Cancer Drug ABSK211](https://longbridge.com/en/news/296302600.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**